

Editas Medicine, Inc. (EDIT)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001650664

Editas Medicine, Inc. EDIT; healthcare	
Grade	E  weakest fifth of 371 graded peers percentile 91.1; sampling error 2.5 points; lower is stronger
Rank	338 of 371
Profitability	E  percentile 84.1
Solvency	C/D  percentile 62.1
Growth and financing	C/D  percentile 58.1
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$120M to \$591M assets total assets \$186.5M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active; fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 9, 2026 214 days before the rescans; latest periodic filing 10-Q received Aug 5, 2026
Last close	\$2.83 2026-10-08; market equity \$434.6M
Price used in grade	None

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 9, 2026

We are a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The promise of genomic medicines is supported by the advancing knowledge of the human genome and by harnessing the progress in technologies for cell therapy, gene therapy, and, most recently, gene editing. We believe this progress sets the stage for us to create medicines with the potential to have a durable benefit for patients. Our core capability in gene editing uses the technology known as CRISPR (clustered, regularly interspaced, short palindromic repeats) to allow us to create molecules that

efficiently and specifically edit DNA.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 84.1						
Gross profitability		not computable	32.2%			one or more required annual facts are missing
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		2.0%	(6.6%)	84.1	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 62.1						
Twelve-month failure probability		0.09%	0.07%	54.7	248	2026-06-30
Altman Z double-prime		(29.91)	(0.31)	80.1	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		3.54x	2.96x	51.6	839	2025-12-31
Growth and financing, sleeve percentile 58.1						
Revenue growth, three-year compound		27.1%	10.0%	24.2	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		(28.7%)	2.1%	92.0	704	2025-12-31
Net share issuance, one year		18.0%	2.5%	58.0	634	2026-02-27


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 74,107,000 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
333	Brookdale Senior Living Inc. (BKD)	89.7	E	
334	Lifeward Ltd. (LFWD)	90.0	E	dilution, late filer
335	Canopy Growth Corp. (CGC)	90.3	E	dilution, fortress balance sheet
336	Aytu Biopharma, Inc. (AYTU)	90.5	E	fortress balance sheet
337	Q32 Bio Inc. (QTTB)	90.8	E	
338	Editas Medicine, Inc. (EDIT) <	91.1	E	fortress balance sheet
339	Dyadic International Inc. (DYAI)	91.4	E	short runway, distress
340	Century Therapeutics, Inc. (IPSC)	91.6	E	dilution, fortress balance sheet
341	Beyond Air, Inc. (XAIR)	91.9	E	dilution, short runway, distress
342	Precision Biosciences Inc. (DTIL)	92.2	E	dilution, fortress balance sheet
343	Elutia Inc. (ELUT)	92.4	E	short runway, fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(11.8%)	8.0%	38
Distance from 52-week high	(31.6%)	(31.4%)	49
EBIT to enterprise value	(51.3%)	(1.5%)	13
Free cash flow yield	(38.0%)	(1.0%)	15
Book value to price	0.24	0.28	47
Sales to price	0.09	0.31	24
Composite equity issuance, five years	82.4%	20.3%	75
Relative strength against the sector, log excess return	(0.34)	(0.14)	38

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail

Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$181.8M
Operating cash flow, four quarters	-\$119.9M
Months of runway	18.2
Days since last periodic filing	65 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	\$5.6M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$160.1M	2025-12-31	2026-03-09	10-K	0001650664-26-000017
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$165.2M	2025-12-31	2026-03-09	10-K	0001650664-26-000017
3	assets	us-gaap:Assets	\$186.5M	2025-12-31	2026-03-09	10-K	0001650664-26-000017
4	assets	us-gaap:Assets	\$341.6M	2024-12-31	2026-03-09	10-K	0001650664-26-000017
5	current assets	us-gaap:AssetsCurrent	\$163.9M	2025-12-31	2026-03-09	10-K	0001650664-26-000017
6	current liabilities	us-gaap:LiabilitiesCurrent	\$46.2M	2025-12-31	2026-03-09	10-K	0001650664-26-000017
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.6B	2025-12-31	2026-03-09	10-K	0001650664-26-000017
8	operating income	us-gaap:OperatingIncomeLoss	-\$160.0M	2025-12-31	2026-03-09	10-K	0001650664-26-000017
9	book equity	us-gaap:StockholdersEquity	\$27.3M	2025-12-31	2026-03-09	10-K	0001650664-26-000017
10	liabilities	us-gaap:Liabilities	\$159.2M	2025-12-31	2026-03-09	10-K	0001650664-26-000017
11	total debt	us-gaap:LongTermDebt	\$57.4M	2024-12-31	2025-03-05	10-K	0001650664-25-000022
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$131.5M	2024-12-31	2026-03-09	10-K	0001650664-26-000017
13	operating income	us-gaap:OperatingIncomeLoss	-\$251.2M	2024-12-31	2026-03-09	10-K	0001650664-26-000017
14	depreciation amortization	us-gaap:Depreciation	\$5.8M	2024-12-31	2026-03-09	10-K	0001650664-26-000017
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$40.5M	2025-12-31	2026-03-09	10-K	0001650664-26-000017
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$32.3M	2024-12-31	2026-03-09	10-K	0001650664-26-000017
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$78.1M	2023-12-31	2025-03-05	10-K	0001650664-25-000022
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$19.7M	2022-12-31	2025-03-05	10-K	0001650664-25-000022
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$607,000	2025-12-31	2026-03-09	10-K	0001650664-26-000017
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$210.3M	2024-12-31	2026-03-09	10-K	0001650664-26-000017
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$8.8M	2024-12-31	2026-03-09	10-K	0001650664-26-000017
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$132.2M	2023-12-31	2025-03-05	10-K	0001650664-25-000022
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4.7M	2023-12-31	2025-03-05	10-K	0001650664-25-000022
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$177.3M	2022-12-31	2025-03-05	10-K	0001650664-25-000022
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4.1M	2022-12-31	2025-03-05	10-K	0001650664-25-000022
26	assets	us-gaap:Assets	\$499.2M	2023-12-31	2025-03-05	10-K	0001650664-25-000022
27	assets	us-gaap:Assets	\$514.3M	2022-12-31	2024-02-28	10-K	0001650664-24-000008
28	shares outstanding	dei:EntityCommonStockSharesOutstanding	97,871,999	2026-02-27	2026-03-09	10-K	0001650664-26-000017
29	shares outstanding	dei:EntityCommonStockSharesOutstanding	82,976,284	2025-02-28	2025-03-05	10-K	0001650664-25-000022